Brad Thompson

1.1k total citations
24 papers, 869 citations indexed

About

Brad Thompson is a scholar working on Infectious Diseases, Genetics and Molecular Biology. According to data from OpenAlex, Brad Thompson has authored 24 papers receiving a total of 869 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Infectious Diseases, 17 papers in Genetics and 7 papers in Molecular Biology. Recurrent topics in Brad Thompson's work include Viral gastroenteritis research and epidemiology (16 papers), Virus-based gene therapy research (16 papers) and Cancer Research and Treatments (5 papers). Brad Thompson is often cited by papers focused on Viral gastroenteritis research and epidemiology (16 papers), Virus-based gene therapy research (16 papers) and Cancer Research and Treatments (5 papers). Brad Thompson collaborates with scholars based in Canada, United States and United Kingdom. Brad Thompson's co-authors include Matt Coffey, Peter Forsyth, Don Morris, David H. George, Mark G. Hamilton, Cheryl A. Palmer, Alan Melcher, Hardev Pandha, Kevin J. Harrington and Romit Chakrabarty and has published in prestigious journals such as Cancer Research, Clinical Cancer Research and The Journal of Infectious Diseases.

In The Last Decade

Brad Thompson

24 papers receiving 851 citations

Peers

Countries citing papers authored by Brad Thompson

Since Specialization

Citations

This map shows the geographic impact of Brad Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Thompson more than expected).

Fields of papers citing papers by Brad Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brad Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Thompson. The network helps show where Brad Thompson may publish in the future.

Co-authorship network of co-authors of Brad Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of Brad Thompson. A scholar is included among the top collaborators of Brad Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Thompson. Brad Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia 2024 ·Gene Therapy ·(unknown), (unknown), Yanlong Pei, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brad Thompson, Cezar M. Khursigara, Leonardo Susta, Sarah K. Wootton	3
2	Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis 2023 ·Gene Therapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Yanlong Pei, Laura P. van Lieshout, Lisa A. Santry, Byram W. Bridle, Khalil Karimi, Brad Thompson, Leonardo Susta, James E. Crowe, Sarah K. Wootton	3
3	AAV-Vectored Expression of Marburg Virus–Neutralizing Antibody MR191 Provides Complete Protection From Challenge in a Guinea Pig Model 2023 ·The Journal of Infectious Diseases ·(unknown), (unknown), Shihua He, (unknown), (unknown), Yanlong Pei, Brad Thompson, Logan Banadyga, Sarah K. Wootton	5
4	Recent Advancements in AAV-Vectored Immunoprophylaxis in the Nonhuman Primate Model 2023 ·Biomedicines ·(unknown), (unknown), (unknown), Brad Thompson, Leonardo Susta, Logan Banadyga, Sarah K. Wootton	5
5	AAV-Vectored Expression of the Vascular Normalizing Agents 3TSR and Fc3TSR, and the Anti-Angiogenic Bevacizumab Extends Survival in a Murine Model of End-Stage Epithelial Ovarian Carcinoma 2022 ·Biomedicines ·Ashley A. Stegelmeier, Lisa A. Santry, (unknown), Kathy Matuszewska, (unknown), (unknown), (unknown), Sylvia P. Thomas, (unknown), (unknown), Yanlong Pei, (unknown), Jacob P. van Vloten, (unknown), Brad Thompson, Pierre Major, Jim Petrik, Byram W. Bridle, Sarah K. Wootton	6
6	Adeno-associated virus mediated expression of monoclonal antibody MR191 protects mice against Marburg virus and provides long-term expression in sheep 2022 ·Gene Therapy ·(unknown), Laura P. van Lieshout, (unknown), Shihua He, Kevin Tierney, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brad Thompson, Khalil Karimi, Byram W. Bridle, Leonardo Susta, Xiangguo Qiu, Logan Banadyga, Sarah K. Wootton	9
7	AAV-monoclonal antibody expression protects mice from Ebola virus without impeding the endogenous antibody response to heterologous challenge 2022 ·Molecular Therapy — Methods & Clinical Development ·Laura P. van Lieshout, (unknown), (unknown), Shihua He, Geoff Soule, Wenjun Zhu, Sylvia P. Thomas, (unknown), Kathy L. Frost, Kevin Tierney, Brad Thompson, Stephanie A. Booth, David Safronetz, Raveendra R. Kulkarni, Byram W. Bridle, Xiangguo Qiu, Logan Banadyga, Sarah K. Wootton	7
8	AAV-mediated delivery of actoxumab and bezlotoxumab results in serum and mucosal antibody concentrations that provide protection from C. difficile toxin challenge 2021 ·Gene Therapy ·(unknown), (unknown), Laura P. van Lieshout, (unknown), Yanlong Pei, Lisa A. Santry, Brad Thompson, Sarah K. Wootton	9
9	A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma 2017 ·Cancer Chemotherapy and Pharmacology ·Devalingam Mahalingam, Christos Fountzilas, Jennifer L. Moseley, (unknown), Hue Tran, Romit Chakrabarty, Giovanni Selvaggi, Matthew Coffey, Brad Thompson, John Sarantopoulos	68
10	The oncolytic virus, pelareorep, as a novel anticancer agent: a review 2015 ·Investigational New Drugs ·Romit Chakrabarty, Hue Tran, Giovanni Selvaggi, (unknown), Brad Thompson, Matt Coffey	51
11	Evaluation of homogeneity and genetic stability of REOLYSIN® (pelareorep) by complete genome sequencing of reovirus after large scale production 2014 ·Applied Microbiology and Biotechnology ·Romit Chakrabarty, Hue Tran, Yves Fortin, Zhenbao Yu, (unknown), J L Kolman, David Onions, (unknown), (unknown), (unknown), Amine Kamen, Brad Thompson, Matt Coffey	7
12	Bio-distribution study of Reolysin® (pelareorep) through a single intravenous infusion in Sprague-Dawley rats 2013 ·Investigational New Drugs ·Romit Chakrabarty, Hue Tran, Iohann Boulay, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Brad Thompson, Matt Coffey	8
13	Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies 2012 ·Clinical Cancer Research ·Eleni Karapanagiotou, Victoria Roulstone, Katie Twigger, (unknown), Mary Anne Tanay, Chris Nutting, Kate Newbold, Martin Gore, James Larkin, Konstantinos N. Syrigos, Matt Coffey, Brad Thompson, K.L. Mettinger, Richard G. Vile, Hardev Pandha, Geoff Hall, Alan Melcher, John Chester, Kevin J. Harrington	151
14	Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway 2012 ·BMC Cancer ·Katie Twigger, Victoria Roulstone, Joan Kyula, Eleni Karapanagiotou, Konstantinos N. Syrigos, Richard Morgan, Christine L. White, Shreerang Bhide, Gerard J. Nuovo, Matt Coffey, Brad Thompson, Adel Jebar, Fiona Errington‐Mais, Alan Melcher, Richard G. Vile, Hardev Pandha, Kevin J. Harrington	46
15	REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors 2012 ·Investigational New Drugs ·Don Morris, Xiaolan Feng, Lisa Difrancesco, Kevin Fonseca, Peter Forsyth, Alexander Paterson, Matt Coffey, Brad Thompson	89
16	Enhanced In vitro and In vivo Cytotoxicity of Combined Reovirus and Radiotherapy 2008 ·Clinical Cancer Research ·Katie Twigger, Laura Vidal, Christine L. White, Johann S. de Bono, Shreerang Bhide, Matt Coffey, Brad Thompson, Richard G. Vile, Lucy Heinemann, Hardev Pandha, Fiona Errington‐Mais, Alan Melcher, Kevin J. Harrington	88
17	A Phase I Trial of Intratumoral Administration of Reovirus in Patients With Histologically Confirmed Recurrent Malignant Gliomas 2008 ·Molecular Therapy ·Peter Forsyth, Glòria Roldán, David H. George, Carla Wallace, Cheryl A. Palmer, Don Morris, Gregory Cairncross, (unknown), James M. Markert, G. Yancey Gillespie, Matt Coffey, Brad Thompson, Mark G. Hamilton	220
18	A Phase I Study to Evaluate Systemic Wild-type Reovirus (REOLYSIN)(R) in Combination With Docetaxel in Patients With Advanced Malignancies 2008 ·View ·(unknown), James Spicer, Andrew Protheroe, (unknown), Matt Coffey, Brad Thompson, Kevin J. Harrington, Hardev Pandha	5
19	In vivo synergy between oncolytic reovirus and gemcitibane in ras-mutated human HCT116 xenografts 2007 ·Cancer Research ·Maureen E. Lane, Jeanne M. Fahey, (unknown), Nancy Hamel, Bo Yu, Brad Thompson, Matt Coffey, Scott Wadler	4
20	Spontaneous Rupture of the Spleen 1954 ·BMJ ·Brad Thompson	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact